KPIs & Operating Metrics(New)
Growth Metrics

Abbott Laboratories (ABT) Gains from Investment Securities (2016 - 2026)

Abbott Laboratories' Gains from Investment Securities history spans 18 years, with the latest figure at -$34.0 million for Q1 2026.

  • On a quarterly basis, Gains from Investment Securities fell 325.0% to -$34.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$44.0 million, a 102.56% decrease, with the full-year FY2025 number at -$18.0 million, down 101.04% from a year prior.
  • Gains from Investment Securities hit -$34.0 million in Q1 2026 for Abbott Laboratories, down from $28.0 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for ABT hit a ceiling of $1.9 billion in Q4 2022 and a floor of -$51.0 million in Q2 2022.
  • Historically, Gains from Investment Securities has averaged $222.4 million across 5 years, with a median of -$3.0 million in 2022.
  • The widest YoY moves for Gains from Investment Securities: up 86700.0% in 2024, down 4700.0% in 2024.
  • Tracing ABT's Gains from Investment Securities over 5 years: stood at $1.9 billion in 2022, then plummeted by 100.11% to -$2.0 million in 2023, then skyrocketed by 86700.0% to $1.7 billion in 2024, then tumbled by 98.38% to $28.0 million in 2025, then crashed by 221.43% to -$34.0 million in 2026.
  • Business Quant data shows Gains from Investment Securities for ABT at -$34.0 million in Q1 2026, $28.0 million in Q4 2025, and -$38.0 million in Q3 2025.